Your browser is no longer supported. Please, upgrade your browser.
IBIO iBio, Inc. daily Stock Chart
iBio, Inc.
Index- P/E- EPS (ttm)-1.18 Insider Own1.10% Shs Outstand79.92M Perf Week5.88%
Market Cap184.10M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float92.53M Perf Month76.84%
Income-39.20M PEG- EPS next Q- Inst Own11.20% Short Float4.32% Perf Quarter385.03%
Sales1.30M P/S141.61 EPS this Y38.70% Inst Trans79.90% Short Ratio0.17 Perf Half Y1308.70%
Book/sh0.05 P/B32.40 EPS next Y- ROA-108.70% Target Price- Perf Year103.77%
Cash/sh0.09 P/C18.41 EPS next 5Y- ROE- 52W Range0.05 - 3.40 Perf YTD550.60%
Dividend- P/FCF- EPS past 5Y-10.10% ROI-57.60% 52W High-52.35% Beta-6.15
Dividend %- Quick Ratio1.70 Sales past 5Y58.00% Gross Margin- 52W Low3140.00% ATR0.18
Employees7 Current Ratio1.70 Sales Q/Q-80.00% Oper. Margin- RSI (14)65.27 Volatility14.34% 14.10%
OptionableNo Debt/Eq8.40 EPS Q/Q73.40% Profit Margin- Rel Volume0.34 Prev Close1.62
ShortableYes LT Debt/Eq8.03 Earnings- Payout- Avg Volume22.98M Price1.62
Recom- SMA2027.66% SMA5043.32% SMA200147.33% Volume0 Change0.00%
May-27-20 11:45AM  Hedge Funds Have Never Been This Bullish On iBio, Inc. (IBIO) Insider Monkey
May-22-20 09:05AM  7 Top-Rated Biotech Stocks to Buy on the Hunt for a Vaccine InvestorPlace
May-21-20 02:44PM  6 Top-Rated Stocks for a Post-Coronavirus-Crisis Bump InvestorPlace +5.07%
Apr-28-20 03:44PM  Why iBio's Stock Is Trading Higher Today Benzinga +22.26%
Apr-27-20 04:15PM  iBio Estimates ~500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility GlobeNewswire
Apr-24-20 07:00AM  The Coronavirus Makes iBio Finally Relevant InvestorPlace -5.25%
Apr-09-20 07:30AM  iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute GlobeNewswire +6.61%
Apr-03-20 05:01AM  IBIO Stock Will Continue to Slide Lower After Speculative COVID-19 Surge InvestorPlace -9.22%
Mar-26-20 04:20PM  iBio Supporting AzarGen Biotechnologies Development of a Rituximab Biosimilar GlobeNewswire +7.14%
07:30AM  iBio Announces Advancement of COVID-19 Vaccine Program GlobeNewswire
Mar-20-20 11:38AM  Dont Waste Time and Risk Capital on Coronavirus Play IBIO Stock InvestorPlace
07:30AM  iBio Joins the Alliance for Biosecurity GlobeNewswire
Mar-18-20 08:00AM  iBio Announces Development of Proprietary COVID-19 Vaccine Candidates GlobeNewswire +40.35%
Mar-13-20 08:08AM  iBio Stock Is Unlikely a Coronavirus Winner and Thus a Real Gamble InvestorPlace +11.89%
Mar-12-20 04:45PM  iBio Announces Leadership Succession, Appoints Thomas F. Isett Co-Chairman & CEO GlobeNewswire -9.49%
Mar-05-20 04:20PM  Dow notches another 900-point loss as benchmark government bond carves out new record low MarketWatch
08:07AM  iBio stock surges 19% premarket on hopes for plans to develop plant-based coronavirus vaccine MarketWatch
Mar-02-20 04:30PM  iBio, Inc. Announces Withdrawal of Proxy Statement Proposal to Amend Its Certificate of Incorporation to Authorize a Possible Reverse Stock Split GlobeNewswire -9.80%
Feb-28-20 10:12AM  iBio shares soar another 174% on hopes for China vaccine partnership MarketWatch +183.24%
Feb-17-20 08:52AM  Here's Why iBio (NYSEMKT:IBIO) Must Play Its Cards Just Right Simply Wall St.
Feb-06-20 04:30PM  iBio, Inc. Announces Postponement of Annual Meeting GlobeNewswire
Feb-04-20 08:54AM  Benzinga Pro's Top 5 Stocks To Watch For Tues., Feb. 4, 2020: GOOGL, DIS, EBAY, F, IBIO Benzinga +61.69%
Feb-03-20 04:15PM  iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine GlobeNewswire
Jan-16-20 08:00AM  iBio, Inc. Announces NYSE American Acceptance of Plan of Compliance GlobeNewswire +8.52%
Jan-06-20 09:15AM  iBio Initiates New Litigation Against Fraunhofer GlobeNewswire -11.39%
Dec-23-19 09:30AM  EdgePoint announces collaboration with iBio CDMO to implement AI/Blockchain driven TrustPoint Vision Technology in its Texas cGMP facility GlobeNewswire -9.26%
08:30AM  iBio Announces Collaboration with EdgePoint AI for Next Gen Quality in Biologics Manufacturing GlobeNewswire
Dec-19-19 11:22AM  Is iBio, Inc.'s (NYSEMKT:IBIO) CEO Being Overpaid? Simply Wall St.
Dec-16-19 04:15PM  iBio Reports Progress on its Bio-Better Rituximab Collaboration with CC-Pharming GlobeNewswire -12.89%
Dec-13-19 05:00PM  iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan GlobeNewswire -7.98%
Dec-10-19 04:44PM  iBio Introduces FastGlycaneering Development Service to Power Recombinant Protein Production GlobeNewswire -9.39%
Dec-03-19 12:31PM  iBio Joins Manufacturing USAs Tissue Biofabrication Initiative GlobeNewswire +41.35%
Dec-02-19 04:15PM  iBio to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference GlobeNewswire +20.04%
Oct-25-19 08:30AM  iBio, Inc. Prices $5,000,000 Public Offering GlobeNewswire -43.26%
Oct-22-19 04:30PM  iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan GlobeNewswire +15.10%
Sep-19-19 01:58PM  One Thing To Remember About The iBio, Inc. (NYSEMKT:IBIO) Share Price Simply Wall St.
Sep-17-19 04:15PM  iBios Collaboration with South Africas AzarGen Biotechnologies Advances to Next Stage GlobeNewswire
Aug-26-19 05:30PM  iBio and CC-Pharming Expand Business Collaboration in China GlobeNewswire -7.43%
Aug-21-19 12:15PM  A Look At Benzinga Pro's Most-Searched Tickers For August 21, 2019 Benzinga -7.87%
Aug-19-19 04:35PM  iBio Inks 3D Bioprinting Agreement GlobeNewswire
Jul-25-19 11:16AM  Did Changing Sentiment Drive iBio's (NYSEMKT:IBIO) Share Price Down A Painful 89%? Simply Wall St.
Jun-19-19 08:00AM  iBio Announces First Agreement for Fill-Finish Services GlobeNewswire
Jun-10-19 01:58PM  How Should Investors React To iBio, Inc.'s (NYSEMKT:IBIO) CEO Pay? Simply Wall St.
Jun-03-19 08:00AM  iBio Launches New Sterile Fill-Finish Services GlobeNewswire
Apr-24-19 02:03PM  What Type Of Shareholder Owns iBio, Inc.'s (NYSEMKT:IBIO)? Simply Wall St.
Apr-01-19 08:30AM  iBio Announces Appointment of Thomas F. Isett to Board of Directors GlobeNewswire
Dec-14-18 08:00AM  iBio Provides Status Update on its Continuing Litigation Against Fraunhofer GlobeNewswire
Dec-03-18 08:00AM  iBio to Present at Brazilian Ministry of Healths Plant-Made Pharmaceutical Meeting GlobeNewswire
Oct-02-18 08:00AM  iBio and CC-Pharming Hold First Design and Strategy Meeting GlobeNewswire +13.53%
Aug-22-18 04:10PM  iBio, Inc. Announces NYSE American Acceptance of Plan of Compliance GlobeNewswire
Jul-09-18 08:00AM  iBio Establishes Strategic Commercial Relationship with CC-Pharming Ltd. of Beijing, China GlobeNewswire +8.00%
Jun-27-18 07:20AM  Free Technical Research on Nektar Therapeutics and Three More Biotech Equities ACCESSWIRE
Jun-26-18 06:59PM  iBio, Inc. Closes $16,000,000 Public Offering GlobeNewswire
Jun-22-18 07:26AM  iBio, Inc. Prices $16,000,000 Public Offering GlobeNewswire
Jun-08-18 04:30PM  iBio, Inc. Announces Completion of 1-For-10 Reverse Stock Split GlobeNewswire
04:01PM  iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan GlobeNewswire
Jun-05-18 08:30AM  iBio and ONEWAY Diagnostica Develop New Products for Brazil GlobeNewswire +10.21%
Jun-04-18 05:46PM  Why iBio Incs (NYSEMKT:IBIO) Ownership Structure Is Important Simply Wall St.
May-31-18 08:30AM  iBio, Inc. Announces Reverse Stock Split GlobeNewswire -7.40%
May-24-18 07:15AM  Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks ACCESSWIRE
Apr-11-18 01:27PM  Should iBio Incs (NYSEMKT:IBIO) Recent Earnings Decline Worry You? Simply Wall St. -9.57%
Mar-14-18 08:30AM  iBio Selects Lead Candidate for its Fibrosis Therapeutics Program GlobeNewswire
Mar-12-18 08:30AM  iBio Patent Issues in China on Protein Glycosylation Modification GlobeNewswire
Mar-07-18 08:45AM  iBio Expands Antibody Development and Production Services to Include Fc Fusion Therapeutics GlobeNewswire +26.09%
Dec-18-17 03:44PM  ETFs with exposure to iBio, Inc. : December 18, 2017 Capital Cube +5.91%
Dec-08-17 02:53PM  iBio Inc (IBIO): Does -31.1% EPS Decline Lately Make It An Underperformer? Simply Wall St.
01:03PM  ETFs with exposure to iBio, Inc. : December 8, 2017 Capital Cube
Nov-30-17 04:15PM  iBio, Inc. Closes $4,500,000 Offering of Common Stock GlobeNewswire
Nov-29-17 09:00AM  iBio, Inc. Prices $4,500,000 Firm Commitment Offering of Common Stock GlobeNewswire -31.61%
Nov-28-17 05:07PM  iBio, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Nov-27-17 02:12PM  ETFs with exposure to iBio, Inc. : November 27, 2017 Capital Cube
Nov-14-17 02:27PM  ETFs with exposure to iBio, Inc. : November 14, 2017 Capital Cube
Nov-13-17 09:20AM  iBio, Inc. :IBIO-US: Earnings Analysis: Q1, 2018 By the Numbers : November 13, 2017 Capital Cube
Nov-08-17 12:00PM  AEMD: Upcoming FDA Meeting Expected to Define U.S. Regulatory Pathway Zacks Small Cap Research
Nov-06-17 05:00PM  iBio, Inc. Initiates Litigation Against Fraunhofer-Gesellschaft in Delaware Chancery Court GlobeNewswire
Oct-30-17 08:30AM  iBio CDMO President to Co-Chair South African Molecular Pharming Conference GlobeNewswire
Oct-24-17 09:39AM  ETFs with exposure to iBio, Inc. : October 24, 2017 Capital Cube -5.51%
Oct-23-17 08:00AM  IBio, Aethlon Agreement, The Biologics Market, and Analysts Target, CFB-03 Update ACCESSWIRE
Oct-18-17 07:00AM  Featured Company News - iBio Announces Large-Scale Manufacturing Collaboration with Aethlon Medical ACCESSWIRE
Oct-16-17 07:15AM  iBio Announces Manufacturing Collaboration with Aethlon Medical GlobeNewswire +5.00%
07:15AM  Aethlon Medical Announces Large-Scale Production Collaboration PR Newswire
Oct-13-17 10:56AM  ETFs with exposure to iBio, Inc. : October 13, 2017 Capital Cube
Oct-05-17 05:36PM  What Are The Drivers Of iBio Incs (IBIO) Risks? Simply Wall St.
Oct-04-17 09:00AM  iBio, Inc. :IBIO-US: Earnings Analysis: Q4, 2017 By the Numbers : October 4, 2017 Capital Cube
Oct-02-17 10:54AM  ETFs with exposure to iBio, Inc. : October 2, 2017 Capital Cube
08:30AM  iBio Appoints James Abbey, Ph.D. as Vice President of Strategic Business Development GlobeNewswire
Sep-20-17 05:40PM  ETFs with exposure to iBio, Inc. : September 20, 2017 Capital Cube +18.81%
08:00AM  iBio, Inc. Intellectual Property Update GlobeNewswire
Sep-19-17 05:55PM  iBio Makes NYSE MKT Section 610(b) Public Announcement GlobeNewswire -11.35%
02:27PM  iBio, Inc. :IBIO-US: Earnings Analysis: 2017 By the Numbers : September 19, 2017 Capital Cube
Sep-18-17 08:00AM  iBio and TheoremDx Collaborate to Develop Proteins for Rapid Diagnostics Testing Products GlobeNewswire +22.84%
Jul-25-17 07:12AM  AzarGen Biotechnologies Granted European Patent for Plant-Made PRODUCTION OF RECOMBINANT HUMAN SURFACTANT PROTEIN-B PR Newswire
Jul-24-17 08:30AM  iBio, Inc. Enters into Common Stock Purchase Agreement for Up to $16.0 Million with Lincoln Park Capital GlobeNewswire
Jul-12-17 01:00PM  Wednesdays Biotech Movers: Ibio Inc (IBIO) Rallies, Ocular Therapeutix Inc (OCUL) Tumbles, Alder Biopharmaceuticals Inc (ALDR) Dives SmarterAnalyst
08:32AM  US Patent Granted to AzarGen Biotechnologies for Synthetic Promoter Technology PR Newswire
Jul-10-17 02:38PM  ETFs with exposure to iBio, Inc. : July 10, 2017 Capital Cube
Jun-05-17 02:21PM  ETFs with exposure to iBio, Inc. : June 5, 2017 Capital Cube
08:30AM  iBio, Inc. to Present Plant-Made Pharmaceutical Platform at Plant-Based Vaccines, Antibodies & Biologics Conference GlobeNewswire
May-25-17 12:41PM  ETFs with exposure to iBio, Inc. : May 25, 2017 Capital Cube
May-24-17 10:27AM  iBio, Inc. :IBIO-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017 Capital Cube
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with Beijing CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology. In addition, the company offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.